Troy Z. Horvat

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

Troy Z. Horvat, Nelly G. Adel, Thu-Oanh Dang et al. · Journal of Clinical Oncology · 2015 · 1.1K citations · Full text

Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML

Maximilian Stahl, Kamal Menghrajani, Andriy Derkach et al. · Blood Advances · 2021 · 181 citations · Full text

Efficacy and safety of checkpoint blockade for treatment of advanced melanoma (mel) in patients (pts) age 80 and older (80+).

Claire F. Friedman, Troy Z. Horvat, Janna Minehart et al. · Journal of Clinical Oncology · 2016 · 47 citations

Drug Safety, Oncology, Age Group +15

Venetoclax Combined with Either a Hypomethylating Agent or Low-Dose Cytarabine Shows Activity in Relapsed and Refractory Myeloid Malignancies

Aaron D. Goldberg, Troy Z. Horvat, Meier Hsu et al. · Blood · 2017 · 23 citations

The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance

Troy Z. Horvat, Joshua J. Pecoraro, Ryan J. Daley et al. · Leukemia Research · 2016 · 22 citations · Full text

Pegaspargase Intolerance, Erwinia Asparaginase, Pathogenesis +5